

**NANOBIOSENSING WITH TARGET AMPLIFICATION, AND NANOSWIMMERS  
CAN BE CONTROLLED BY MAGNETIC FIELDS AND FACILITATE GENE  
THERAPY AND NANOMEDICINE APPLICATIONS**

**Moataz Dowaidar**<sup>1,2</sup>

<sup>1</sup> Department of Bioengineering, King Fahd University of Petroleum and Minerals (KFUPM), Dhahran 31261, Saudi Arabia.

<sup>2</sup> Interdisciplinary Research Center for Hydrogen and Energy Storage (IRC-HES), King Fahd University of Petroleum and Minerals (KFUPM), Dhahran, 31261, Saudi Arabia.

**Abstract**

Nanobiosensing with target amplification is one such example. In this scenario, "activator" nanoparticles stimulate the target location, such as a tumor, resulting in spatial amplification of a tumor-triggered phenomenon-of-interest (POI). The typical targeting approach, which relies on the human vascular system to transport nanoparticles, is inefficient and is considered a brute-force search from a computing standpoint. By evaluating the observable properties of these nanoswimmers, which are controlled by magnetic fields created by electromagnetic coils, an external tracking system is utilized to explore the tissue environment. The stochastic movement of numerous loosely connected, disc-shaped components in the system results in deterministic locomotion. When each component is programmed to oscillate omnidirectionally along its radius, expanding and contracting in response to varying environmental signals, the system can collectively locomote towards the source of the environmental signal. The main goal is to enable interoperability while developing multiple simulation components for computational nanobiosensing with different and non-interoperable interfaces. The accuracy of the computational models and algorithms should be tested utilizing multi-physics in silico platforms that simulate the targeting of externally manipulable or self-regulatable nanorobots. To minimize the rates of erroneous and missed detection, "natural" deep learning approaches might be used to train mathematical models for in vivo target identification. The particle stretching approach for creating worm-like structures capable of low-Reynolds-number propulsion when actuated by a rotating magnetic field is one possibility. To replicate the function of an MRI, a sensor array made up of several magnetoresistive sensors might be utilized to precisely place nanorobots. Such systems would also need to be developed in three dimensions, with more complicated locomotive behavior of components and aggregates inside blood flows. In conclusion, computational nanobiosensing is to improve in vivo POI targeting and understanding of POI-induced gradients.

Computing in live organisms (also known as *in vivo* computation) seeks to get a better understanding of the living host environment by treating natural *in vivo* events as data processing. Nanobiosensing with target amplification is one such example. In this scenario, "activator" nanoparticles stimulate the target location, such as a tumor, resulting in spatial amplification of a tumor-triggered phenomenon-of-interest (POI). As a result, [1-8], the traditional targeting approach, which relies on the human vascular system to transport nanoparticles, is inefficient and is considered a brute-force search in terms of computing. According to statistical data from the previous decade [9], just 0.7 percent of administered nanoparticles reached their destinations. For nanobiosensing, externally manipulable or self-regulatable nanorobots are preferable to non-manipulable nanoparticles.

Nanoparticles, on the one hand, can be substituted for swarms of externally manipulable nanorobots, such as nanoswimmers made of iron oxide magnetic nanoparticles [10-13]. By evaluating the observable properties of these nanoswimmers, which are controlled by magnetic fields created by electromagnetic coils, an external tracking system (i.e., a tracking system outside the tissue environment) is utilized to explore the tissue environment. To address the ambiguity in swimming directions by supplying an intended actuation force for the nanoswimmers, a combination of rotating and static magnetic fields can be created using an approximate Helmholtz coil system [14-16]. As a result, we might envision a unique architecture for nanobiosensing that is externally manipulable *in vivo* computation. Multiple nanorobots work together in this framework to locate the best solution (i.e., the target location) by traveling across the domain (i.e., the high-risk tissue) while being guided by a programmed external force (i.e., the steering magnetic field). Some features of high-risk tissue, such as passive physical qualities (e.g., peritumoral vascular tortuosity) and active biochemical properties, are linked to the POI (e.g., extravascular coagulation caused by photothermal heating localized around the tumor site). These biological features, in turn, can cause changes in the nanorobots' paths and vitality, which can be evaluated using an imaging technique like an MRI. The external tracking system's observations of the nanorobots' paths and vitality can thus be interpreted as *in vivo* "biological gradients" surrounding the tumor location [14]. Following that, the intensity of the biological gradient detected by each swarm of nanorobots is gathered and evaluated centrally by the external system, which makes centralized decisions regarding the nanorobots' next movement and maneuvers.

Nanoparticles, on the other hand, can be substituted by a swarm of self-regulatable nanorobots, such as those described in [17], where Li et al. describe a collective robotic system based on the idea of "particle robotics." The stochastic movement of numerous loosely connected, disc-shaped components in the system results in deterministic locomotion. In the absence of external stimuli, the system can only move randomly, whereas when each component is programmed to oscillate omnidirectionally along its radius, expanding and contracting in response to the varying environmental signals, the system can collectively locomote towards the source of the environmental signal. As a result, we may envision a parallel architecture for nanobiosensing that is self-regulatable *in vivo* computing. Self-regulating nanorobots, for example, rely on chemically driven motors to move them through aqueous solutions by generating local differences in concentration, electrical potential, and gas bubbles via surface reactions [18].

Through the weak coupling between them (e.g., push-and-pull owing to individual components contracting and expanding), the intensity of the biological gradient detected by each nanorobot is broadcast to its surrounding components. Individual component data is processed locally, again through interactions between neighbors, and in a distributed manner without the use of a central monitoring system. Following that, decentralized decision-making and self-maneuvering occurs, resulting in collective locomotion towards the POI.

In essence, in-vivo computing that is either externally manipulable or self-regulatable provides an intriguing parallel between learning-oriented nanobiosensing and iterative optimization. The most difficult theoretical problem to solve is determining the best solution and evaluating the objective function (biological gradient) under a variety of in vivo physical limitations (e.g., the discrete blood vessels, the finite speed and lifespan of each nanorobot). Models, algorithms, and in silico trials are three complimentary techniques that might be used to solve the problem.

Anatomically accurate representations of biological gradients and vascular networks, as well as nanorobot propagation properties in blood arteries, should be included in new computer models. For cases where the POI-triggered biological gradient changes with time and has many agents, population-based trial and error problem-solvers with a metaheuristic or stochastic optimization character (i.e., the agents that represent the candidate solutions are evaluated according to their fitness in the biological gradient field, and updated according to some specific evolution schema) could be developed. As a result, the solvers must be able to adapt to nonstationary optimization landscapes [19]. For biological gradients that are time-invariant and contain a single peak, gradient-based iterative problem solutions might be created.

Due to their small size, computational agents in the form of swarms of nanorobots are unable to communicate effectively with one another and lack sufficient computing power and storage capacity. Furthermore, the restricted number of swarms and the finite speed of agents at the nanoscale to traverse the whole solution space (i.e., the host environment) results in longer processing time for each iteration, lowering computational capacity even further. In addition, novel natural computing techniques must consider the practical limits of in-vivo computation.

Landscape uncertainties due to random interactions between nanorobots and the host environment, steering imperfections due to limitations of current nanorobotic technologies, quantization noise due to discrete vascular networks, finite velocities and lifespans of nanorobots due to diffusion and degeneration losses, and other internal noise sources should all be considered among these practical constraints. Unusual nanorobot-enabled feature extraction methods may be created to evaluate landscape roughness, as well as its peak number, height, separation, and clustering, which give significant information on the effect of the POI condition on the in vivo environment. To minimize the rates of erroneous and missed detection, "natural" deep learning approaches might be used to train mathematical models for in vivo target identification. Furthermore, in nanobiosensing, balancing precision (without sacrificing targeted efficiency) with other factors such as flexibility and resilience is critical, and addressing such alternate aims might open up new research avenues.

The accuracy of the computational models and algorithms should be tested utilizing multi-physics in silico platforms that simulate the targeting of externally manipulable or self-regulatable nanorobots. The main goal is to enable interoperability while developing multiple simulation components for computational nanobiosensing with different and non-interoperable interfaces. The simulators should simulate the functions and interactions of the nanobiosensor system components (controlling and steering or self-regulating nanorobots, vascular networks, nanorobot movements and disturbances, and so on) that are part of the framework. In essence, a lab-on-a-nanobiosensing-simulator could be built, and the performance of the nanobiosensing system in various usage scenarios could be assessed using this simulator as a measurable, repeatable, and low-cost tool.

The main experimental challenge is to create appropriate nanorobots that can operate in a fluidic environment with low Reynolds numbers. The Stokes flow equation, which is linear and follows the reversibility of motion, can adequately explain the fluid dynamics of externally manipulable nanorobots [13]. The Scallop theorem is the outcome of these properties: reciprocating motion in the Stokes flow does not function for nanorobots that are free of external forces and external moments. In such settings, there are three design challenges for magnetically propelled nanorobots: (1) Given that the Scallop theorem applies to most biological nanorobots, how could non-reciprocal motion be achieved? (2) How do you manage a swarm of nanorobots because controlling them individually would be difficult? It's worth noting that each swarm's enormous number of nanorobots can provide operational redundancy (i.e., even if some nanorobots stop functioning, the swarm itself may still function). (3) How can nanorobots be made to tow and release cargo? The particle stretching approach [20] for creating worm-like structures capable of low-Reynolds-number propulsion when actuated by a rotating magnetic field is one possibility.

Multifunctional magnetic nanoparticles developed for drug delivery and molecular imaging can also meet the criteria of low-Reynolds number propulsion, biocompatibility, and active targeting after stretching. To replicate the function of an MRI, a sensor array made up of several magnetoresistive sensors might be utilized to precisely place nanorobots.

It's worth noting that the interactions between self-regulatable nanorobots (such as expansion and contraction in particle robotics) have a far bigger significance than the usual magnetic and hydrodynamic interactions between nanoparticles. The former performs information output in response to external stimuli such as magnetic induction, light, and sound, whereas the latter only performs information output in response to external stimuli such as magnetic induction, light sources, and sound. As a result, appropriate methods that mimic the function of contacts in particle robots at the nanoscale would be required. It would also be required to guarantee that nanorobot components are able to move independently in order to engage with each other at first. For clinically relevant applications, the number of components should be sufficient, with their overall speed being sufficient and their size being sufficient. Such systems would also need to be developed in three dimensions, with more complicated locomotive behavior of components and aggregates inside low-Reynolds-number blood flows [21].

In conclusion, computational nanobiosensing is to improve in vivo POI targeting and understanding of POI-induced biological gradients. Medical imaging and sensing, natural and evolutionary computing, micro- and nanorobotics, and nanomaterial-based pharmaceutical development are all needed in this emerging sector.

## References

- 1.K. Seidi, H. A. Neubauer, R. Moriggl, R. Jahanban-Esfahlan and T. Javaheri, "Tumor target amplification: Implications for nano drug delivery systems", *J. Controlled Release*, vol. 275, pp. 142-161, Apr. 2018.
- 2.M. Overchuk and G. Zheng, "Overcoming obstacles in the tumor microenvironment: Recent advancements in nanoparticle delivery for cancer theranostics", *Biomaterials*, vol. 156, pp. 217-237, Feb. 2018.
- 3.H. Kim, J. Lee, C. Oh and J.-H. Park, "Cooperative tumour cell membrane targeted phototherapy", *Nature Commun.*, vol. 8, no. 15880, pp. 1-10, 2017.
- 4.B. Zhang et al., "Fibrin-targeting peptide CREKA-conjugated multi-walled carbon nanotubes for self-amplified photothermal therapy of tumor", *Biomaterials*, vol. 79, pp. 46-55, Feb. 2016.
- 5.E. J. Kwon, J. H. Lo and S. N. Bhatia, "Smart nanosystems: Bio-inspired technologies that interact with the host environment", *Proc. Nat. Acad. Sci. USA*, vol. 112, no. 47, pp. 14460-14466, Nov. 2015.
- 6.G. von Maltzahn et al., "Nanoparticles that communicate in vivo to amplify tumour targeting", *Nature Mater.*, vol. 10, pp. 545-552, Jun. 2011.
- 7.J.-H. Park et al., "Cooperative nanoparticles for tumor detection and photothermally triggered drug delivery", *Adv. Mater.*, vol. 22, pp. 880-885, Feb. 2010.
- 8.J.-H. Park et al., "Cooperative nanomaterial system to sensitize target and treat tumors", *Proc. Nat. Acad. Sci. USA*, vol. 107, no. 3, pp. 981-986, Jan. 2010.
- 9.S. Wilhelm et al., "Analysis of nanoparticle delivery to tumours", *Nature Rev. Mater.*, vol. 1, no. 5, pp. 16014, 2016.
- 10.L. Mertz, "Tiny conveyance: Micro- and nanorobots prepare to advance medicine", *IEEE Pulse*, vol. 9, no. 1, pp. 19-23, Jan./Feb. 2018.
- 11.U. K. Cheang, H. Kim, D. Milutinovic, J. Choi and M. J. Kim, "Feedback control of robotic achiral microswimmers", *J. Bionic. Eng.*, vol. 14, no. 2, pp. 245-259, 2017.
- 12.U. K. Cheang, F. Meshkati, H. Kim, K. Lee, H. C. Fu and M. J. Kim, "Versatile microrobotics using simple modular subunits", *Sci. Rep.*, vol. 6, pp. 30472, Jul. 2016.
- 13.U. K. Cheang and M. J. Kim, "Self-assembly of robotic micro- and nanoswimmers using magnetic nanoparticles", *J. Nanopart. Res.*, vol. 17, no. 145, pp. 1-11, 2015.

14. Y. Chen, M. Ali, S. Shi and U. K. Cheang, "Biosensing-by-learning direct targeting strategy for enhanced tumor sensitization", *IEEE Trans. Nanobiosci.*, vol. 18, no. 3, pp. 498-509, Jul. 2019.
15. Y. Chen, S. Shi, X. Yao and T. Nakano, "Touchable computing: Computing-inspired bio-detection", *IEEE Trans. Nanobiosci.*, vol. 16, no. 8, pp. 810-821, Dec. 2017.
16. Y. Chen, T. Nakano, P. Kosmas, C. Yuen, A. V. Vasilakos and M. Asvial, "Green touchable nanorobotic sensor networks", *IEEE Commun. Mag.*, vol. 54, no. 11, pp. 136-142, Nov. 2016.
17. S. Li et al., "Particle robotics based on statistical mechanics of loosely coupled components", *Nature*, vol. 567, pp. 361-365, Mar. 2019.
18. J. Li, B. de Avila, W. Gao, L. Zhang and J. Wang, "Micro/nanorobots for biomedicine: Delivery surgery sensing and detoxification", *Sci. Rob.*, vol. 2, no. 4, pp. eaam6431, 2017.
19. A. J. Rezaee, "Particle swarm optimisation for dynamic optimisation problems: A review", *Neural Comput.*, vol. 25, no. 7, pp. 1507-1516, 2014.
20. J. A. Champion, Y. K. Katare and S. Mitragotri, "Making polymeric micro- and nanoparticles of complex shapes", *Proc. Nat. Acad. Sci. USA*, vol. 104, no. 29, pp. 11901-11904, Jul. 2007.
21. M. Sitti, "Bio-inspired robotic collectives", *Nature*, vol. 567, pp. 314-315, Mar. 2019.
22. Abdelhamid, H. N., M. Dowaidar, M. Hällbrink, and Ü. Langel. 2019. "Cell Penetrating Peptides-Hierarchical Porous Zeolitic Imidazolate Frameworks Nanoparticles: An Efficient Gene Delivery Platform." *SSRN Electron. J.* [https://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=3435895](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3435895).
23. Abdelhamid, Hani Nasser, Moataz Dowaidar, Mattias Hällbrink, and Ülo Langel. 2020. "Gene Delivery Using Cell Penetrating Peptides-Zeolitic Imidazolate Frameworks." *Microporous and Mesoporous Materials: The Official Journal of the International Zeolite Association* 300 (June): 110173. <https://doi.org/10.1016/j.micromeso.2020.110173>.
24. Abdelhamid, Hani Nasser, Moataz Dowaidar, and Ülo Langel. 2020. "Carbonized Chitosan Encapsulated Hierarchical Porous Zeolitic Imidazolate Frameworks Nanoparticles for Gene Delivery." *Microporous and Mesoporous Materials: The Official Journal of the International Zeolite Association* 302 (August): 110200. <https://doi.org/10.1016/j.micromeso.2020.110200>.
25. Ahmad, Almeman, Khalaf Hassan, Rasool Semaab, Moataz Dowaidar, and Al Orainy Mohammad. 2013. "The Impact of CYP2C19 Polymorphism on Platelet Reactivity for Guiding Clopidogrel Treatment and Cost Analysis." *Journal of the Saudi Heart Association* 25 (2): 107. <https://doi.org/10.1016/j.jsha.2013.03.005>.
26. Algahsham, Abdullah, Ahmad A. A. Settin, Ahmad Ali, and Hisham Ismail. n.d. "Association of MTHFR C677T and A1298C Polymorphisms with Hypertension among Saudi Subjects from Qassim Region." *International Journal of Health Sciences* 6 (1). Accessed June 18, 2021. <http://ijhs.org.sa/index.php/journal/article/view/312>.

27. Alghasham, Abdullah, Hisham Ismail, Moataz Dowaidar, and Ahmad A. Settin. 2011. "Methylenetetrahydrofolate Reductase (MTHFR) and Angiotensin Converting Enzyme (ACE) Gene Polymorphisms among Saudi Population from Qassim Region." *International Journal of Health Sciences* 5 (2 Suppl 1): 3–4. <https://www.ncbi.nlm.nih.gov/pubmed/23284552>.
28. Alghasham, Abdullah, Ahmad Ali, Hisham Ismail, Moataz Dowaidar, and Ahmad A. Settin. 2012. "CYP2J2 -50 G/T and ADRB2 G46A Gene Polymorphisms in Saudi Subjects with Hypertension." *Genetic Testing and Molecular Biomarkers* 16 (9): 1027–31. <https://doi.org/10.1089/gtmb.2012.0006>.
29. Alghasham, Abdullah, Ahmad A. Settin, Ahmad Ali, Moataz Dowaidar, and Hisham Ismail. 2012a. "Association of MTHFR C677T and A1298C Gene Polymorphisms with Hypertension." *International Journal of Health Sciences* 6 (1): 3–11. <https://doi.org/10.12816/0005968>.
30. Moataz Dowaidar. 2012b. "Association of MTHFR C677T and A1298C Gene Polymorphisms with Hypertension." *International Journal of Health Sciences* 6 (1): 3–11. <https://doi.org/10.12816/0005968>.
31. Ali, Ahmad, Abdullah Alghasham, Hisham Ismail, Moataz Dowaidar, and Ahmad Settin. 2013. "ACE I/D and eNOS E298D Gene Polymorphisms in Saudi Subjects with Hypertension." *Journal of the Renin-Angiotensin-Aldosterone System: JRAAS* 14 (4): 348–53. <https://doi.org/10.1177/1470320312459976>.
32. Ali, Ahmed A. A., Nahla M. Wassim, Moataz M. Dowaidar, and Ahmed E. Yaseen. 2013a. "Genetic Polymorphism of CYP2D6 Gene among Egyptian Hypertensive Cases." *The Journal of Basic & Applied Zoology* 66 (4): 228–33. <https://doi.org/10.1016/j.jobaz.2012.12.002>.
33. Ali, Ahmed A. A., Nahla M. Wassim, Moataz Dowaidar, and Ahmed E. Yaseen. 2013b. "Association of eNOS (E298D) and CYP2J2 (–50G/T) Gene Polymorphisms with Hypertension among Egyptian Cases." *The Journal of Basic & Applied Zoology* 66 (4): 234–41. <https://doi.org/10.1016/j.jobaz.2012.12.001>.
34. Moataz Dowaidar. 2013c. "Association of eNOS (E298D) and CYP2J2 (–50G/T) Gene Polymorphisms with Hypertension among Egyptian Cases." *The Journal of Basic & Applied Zoology* 66 (4): 234–41. <https://doi.org/10.1016/j.jobaz.2012.12.001>.
35. Aljarallah, Badr, Ahmed Ali, Moataz Dowaidar, and Ahmad Settin. 2011. "Prevalence of  $\alpha$ -1-Antitrypsin Gene Mutations in Saudi Arabia." *Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association* 17 (4): 256–60. <https://doi.org/10.4103/1319-3767.82580>.
36. Dowaidar, M., M. Gustin, C. P. Cerrato, and H. Margus. 2017. "Role of Autophagy in PepFect14 Transfection." <https://www.diva-portal.org/smash/record.jsf?pid=diva2:1077716>.
37. Dowaidar, M., J. Regberg, D. A. Dobchev, and T. Lehto. 2017. "Refinement of a Quantitative Structure–activity Relationship Model for Prediction of Cell-Penetrating Peptide Based Transfection Systems." *International Journal of*. <https://link.springer.com/content/pdf/10.1007/s10989-016-9542-8.pdf>.

38. Dowaidar, Moataz. 2017. "In-Silico Design of Peptide-Based Transfection Systems, in-Vitro Validation, and up-Take Pathways Investigation." Department of Neurochemistry, Stockholm University.
39. Moataz Dowaidar. 2018. "Chimeric Gene Delivery Vectors : Design, Synthesis, and Mechanisms from Transcriptomics Analysis." Department of Biochemistry and Biophysics, Stockholm University. <https://www.diva-portal.org/smash/record.jsf?pid=diva2:1242000>.
40. Moataz Dowaidar. 2021a. "Cardiometabolic Conditions Could Be Related to Vitamin D Deficiency. The Genetic Determinants That Affect Vitamin D Pathways May Be Solved with Nanomedicines." <https://doi.org/10.31219/osf.io/nqewr>.
41. Moataz Dowaidar. 2021b. "Different Insulin Resistance and Inflammation Pathways Are Influenced by Genetic Factors in Metabolic Syndrome. Gene Therapy Enables Early Recognition and Treatment of the Genetic Factors." <https://doi.org/10.31219/osf.io/gqwj2>.
42. Moataz Dowaidar. 2021c. "Gene Therapy Has Been Shown to Be Valuable for Understanding Complex Disease Pathophysiologies. The Medical Profession as a Whole Will Have to Invest in Specialized Investigations." <https://doi.org/10.31219/osf.io/8fg9y>.
43. Moataz Dowaidar. 2021d. "Genetic and Epigenetic Discoveries Hold Promising Avenues in Cardiovascular Prevention and Management (CVDs). Key Nucleic Acids Are Being Researched and Developed for Medicinal Use." <https://doi.org/10.31219/osf.io/hk7pe>.
44. Moataz Dowaidar. 2021e. "Genome Editing Can Now Be Carried out in an Isogenic Setting. It Can Be Effectively Transmitted to Somatic Tissues in Mice, but Not to Humans. Despite These Doubts, CRIS Has Great Potential as a Medical Promise." <https://doi.org/10.31219/osf.io/4rn3v>.
45. Moataz Dowaidar. 2021f. "Genome-Wide Association Experiments Have Uncovered a Slew of Cardiometabolic Trait-Associated Variants. This Information Can Be Useful in the Implementation of New Diagnostic and Treatment Strategies." <https://doi.org/10.31219/osf.io/4vws8>.
46. Moataz Dowaidar. 2021g. "Genome-Wide Association Studies (GWAS) Have Revolutionized Our View of Human Health and Disease Genetics and Offered Novel Gene Therapy Targets." <https://doi.org/10.31219/osf.io/rvm3z>.
47. Moataz Dowaidar. 2021h. "Metabolic Syndrome\_ the Presence of Inflammatory Mechanisms in Abdominal Obesity Is Undeniable, Gene Therapy Using Nanoparticles and Adenoviruses Technologies Is Promising." <https://doi.org/10.31219/osf.io/2j5xt>.
48. Moataz Dowaidar. 2021i. "miRNAs May Be Used as Preventive Agents for Metabolic Diseases in the near Future. Understanding the Interplay between pro-Adipogenic\_ and Anti-Ad Pipogenic miRNA' Could Lead to New Biomarkers." <https://doi.org/10.31219/osf.io/3dr8c>.
49. Moataz Dowaidar. 2021j. "Nanomedicine Has Elegantly Attempted to Cure Multiple Gene Polymorphisms and Mutations in Cardiovascular Diseases Using Gene Therapy Techniques." <https://doi.org/10.31219/osf.io/d3x8g>.



50. Moataz Dowaidar. 2021k. “Thrombosis Pathways and Therapeutic Strategies.” <https://doi.org/10.31219/osf.io/57vyz>.
51. Moataz Dowaidar. 2021l. “What Genomic Research Has Told Us about the Obesity and Its Possible Gene Therapy Targets.” <https://doi.org/10.31219/osf.io/ym49s>.
52. Moataz Dowaidar. 2021m. “Exosomes Can Make the Use of Circulating miRNA as a Biomarker More Feasible. The Aim of Gene Therapy Should Be to Learn Everything There Is to Know about miRNA Activity.” <https://doi.org/10.31219/osf.io/edkua>.
53. Moataz Dowaidar. 2021n. “Anti-Sense Pathways Have Been Generated Using siRNA. The Liver and Other Often Used Organs Will Now Be Targeted.” <https://doi.org/10.31219/osf.io/m6xvp>.
54. Moataz Dowaidar. 2021o. “CrisPR/CRIS Systems Are Highly Effective and Useful for Genomic Manipulation. Despite This, Cardiac Treatment Remains Difficult due to Existing Genome Editing and Delivery Processes.” <https://doi.org/10.31219/osf.io/3nwzd>.
55. Moataz Dowaidar. 2021p. “Discoveries in Gene-Environment Interactions That Influence CVD, Lipid Traits, Obesity, Diabetes, and Hypertension Appear to Be Able to Influence Gene Therapy.” <https://doi.org/10.31219/osf.io/cr5af>.
56. Moataz Dowaidar. 2021q. “Genome Editing’s Potential Target Diseases in the Cardiovascular Field.” <https://doi.org/10.31219/osf.io/gc23p>.
57. Moataz Dowaidar. 2021r. “Key Genetic Factors in the Metabolic Syndrome Predisposition Which May Be a Therapeutic Options by Gene Therapy.” <https://doi.org/10.31219/osf.io/f38sk>.
58. Moataz Dowaidar. 2021s. “miRNA Can Be a Part of Both the Onset and Cure of Coronary Heart Disease.” <https://doi.org/10.31219/osf.io/teqh8>.
59. Moataz Dowaidar. 2021t. “Preclinical Studies and Clinical Trials Have Sparked Interest in Certain Biological Medications for Atherosclerotic Coronary Heart Disease.” <https://doi.org/10.31219/osf.io/ts8mh>.
60. Moataz Dowaidar. 2021u. “Researchers Would Be Able to Develop a Detailed Picture of Chromatin in Disease, Which Would Be Useful for Gene Therapy.” <https://doi.org/10.31219/osf.io/m9z48>.
61. Moataz Dowaidar. 2021v. “The Cardiometabolic-Based Chronic Disease Model Lays the Foundations for Accurate, Evidence-Based Preventive Targeting and Gene Therapy.” <https://doi.org/10.31219/osf.io/up9z4>.
62. Moataz Dowaidar. 2021w. “2D MOFs Have Unique Features for Biological Applications. They Can Be Utilized for Gene Therapy, Bioimaging, Biosensing, Photodynamic Therapy, and Tissue Engineering.” <https://doi.org/10.31219/osf.io/4q9ct>.
63. Moataz Dowaidar. 2021x. “3D Bioprinting for Enhanced Vascularization, and Gene Editing to Provide a More Favorable Immunological Response Are Just Some of the Potential Uses of Carbon Materials.” <https://doi.org/10.31219/osf.io/v2xy8>.
64. Moataz Dowaidar. 2021y. “Anderson–Fabry Disease Can Be a Target for Gene Therapy.” <https://doi.org/10.31219/osf.io/tcgka>.

65. Moataz Dowaidar. 2021z. “Antisense Oligonucleotides (ASOs) and CRISPR Systems Are Promising Gene Therapy Treatments for Alzheimer’s Disease.” <https://doi.org/10.31219/osf.io/ws796>.
66. Moataz Dowaidar. 2021aa. “Any Alteration in PPAR Genomic Sequence, Splicing Pattern, or PTM Is Likely to Cause Major Alterations in Its Function. In Personalized Medicine, Such Data Becomes More Significant in Gene Therapy Design.” <https://doi.org/10.31219/osf.io/y8n79>.
67. Moataz Dowaidar. 2021ab. “Applying Genome-Wide Association Technology to Brain Diseases Enables the Discovery of lncRNAs Targets for Gene Therapy.” <https://doi.org/10.31219/osf.io/hm4eu>.
68. Moataz Dowaidar. 2021ac. “Autophagy and Proteostasis Adjustment Role in Normal Brain Function and Neurodegenerative Disorders.” <https://doi.org/10.31219/osf.io/m4yra>.
69. Moataz Dowaidar. 2021ad. “Basal Ganglia-Cerebellar and Brainstem-Cerebellar Circuits May Interact Improperly with Dystonia. Linking Network Disruptions to Cell Failure Will Enable Understanding Pathophysiology and Designing Gene Therapy Methods.” <https://doi.org/10.31219/osf.io/8w35s>.
70. Moataz Dowaidar. 2021ae. “Blood Products Are Used to Treat a Multitude of Diseases, so the Blood Transfusion System Needs to Be Enhanced. CRISPR/Cas9 Has Made It Viable to Make HLA Class I-Deleted Blood Products to Avoid Rejection.” <https://doi.org/10.31219/osf.io/egr3n>.
71. Moataz Dowaidar. 2021af. “Calixarenes (CAs) Are Promising in Biomedicine, Biosensing, Bioimaging and Gene Delivery Systems.” <https://doi.org/10.31219/osf.io/n9vjy>.
72. Moataz Dowaidar. 2021ag. “CAR T Cell Research Has Quickly Advanced from the Bench to the Clinic and Back. The Results of the Trials Have Revealed New Mechanisms.” <https://doi.org/10.31219/osf.io/f9wm7>.
73. Moataz Dowaidar. 2021ah. “CAR T-Cell Treatment Remains Clinically Challenging. Therapeutic Strategies May Be Designed to Cut off Immunotherapy Utilizing Safety Switches.” <https://doi.org/10.31219/osf.io/s7x4y>.
74. Moataz Dowaidar. 2021ai. “Central Nervous System Gene Therapy Has Entered a New Development Paradigm. New Techniques Are Being Employed for a Wide Range of Illness Indications and Pathways.” <https://doi.org/10.31219/osf.io/j49wz>.
75. Moataz Dowaidar. 2021aj. “Chronic Obstructive Pulmonary Condition (COPD) Is a Prevalent, Preventable, and Curable Illness with Persistent Respiratory Symptoms and Airflow Limitation.” <https://doi.org/10.31219/osf.io/vkdut>.
76. Moataz Dowaidar. 2021ak. “CircRNAs Have the Potential to Aid in the Diagnosis and Treatment of Lipid Diseases.” <https://doi.org/10.31219/osf.io/y3hp4>.
77. Moataz Dowaidar. 2021al. “Clinical Symptoms, Underlying Pathogenesis, and the Prospect of Tailored Therapies Have All Benefited from Genetic Discoveries in Parkinson’s Disease.” <https://doi.org/10.31219/osf.io/pdzqb>.

78. Moataz Dowaidar. 2021am. “Code Distribution of siRNA for Cancer Genes such as p53 and Bcl2 Family Genes Has Demonstrated Efficacy in Killing Cancer Cells. Nanoparticles Can Produce a Surface Where Numerous Drugs May Be Coupled, Allowing Combinatory Treatment.” <https://doi.org/10.31219/osf.io/hvcese>.
79. Moataz Dowaidar. 2021an. “Cognitive Deficiencies Pathophysiology Are Mainly an Unknown Area. Curing the Neurological Conditions Could Be an Objective for Gene Therapy.” <https://doi.org/10.31219/osf.io/23xf8>.
80. Moataz Dowaidar. 2021ao. “CRISPR-Based Gene Editing Is Presently Being Tried in Many Clinical Trials.” <https://doi.org/10.31219/osf.io/qbngx>.
81. Moataz Dowaidar. 2021ap. “CRISPR–Cas9 Gene Editing as a Tool for Developing Immunotherapy for Cancer.” <https://doi.org/10.31219/osf.io/dvr4t>.
82. Moataz Dowaidar. 2021aq. “CRISPR/Cas System Research Has Advanced Significantly in Biological sciences. There Are Still Many Challenges to Effective Delivery before Efficient Gene Editing May Be Achieved.” <https://doi.org/10.31219/osf.io/mc26v>.
83. Moataz Dowaidar. 2021ar. “CRISPR/Cas9 Genome Editing Technology Applications in Biological and Biomedical Fields.” <https://doi.org/10.31219/osf.io/ctqbe>.
84. Moataz Dowaidar. 2021as. “Critical Limb Ischemia Potential Gene Therapy Strategies.” <https://doi.org/10.31219/osf.io/aqcpt>.
85. Moataz Dowaidar. 2021at. “Deep Learning Algorithms for scRNAseq Analysis Have Yielded Positive Results, but There Are Still More Promising Ways That Need to Be Developed for Regenerative Medicine.” <https://doi.org/10.31219/osf.io/dh2pt>.
86. Moataz Dowaidar. 2021au. “Depression May Be Epigenetically Controlled by miRNAs Making It a Diagnostic or Gene Therapy Target.” <https://doi.org/10.31219/osf.io/fw65m>.
87. Moataz Dowaidar. 2021av. “Dermatophytes: Role of Host Genetics in the Development of Illness.” <https://doi.org/10.31219/osf.io/mf3bu>.
88. Moataz Dowaidar. 2021aw. “Developments in Biomedical Technology Will Increase the Importance of mRNA in Treating Brain Tumors, as Well as Other Malignancies.” <https://doi.org/10.31219/osf.io/tvj5x>.
89. Moataz Dowaidar. 2021ax. “Downstream Processing of Virus, Virus-like Particles and Nanoparticulate Inclusion Bodies to Be Used as Gene Delivery Vehicles for Human Gene Therapy Applications.” <https://doi.org/10.31219/osf.io/exa3q>.
90. Moataz Dowaidar. 2021ay. “Dravet Syndrome Is a Severe Developmental and Epileptic Encephalopathy. Fenfluramine and Gene Therapy Are Promising.” <https://doi.org/10.31219/osf.io/zvq8y>.
91. Moataz Dowaidar. 2021az. “Exosomes’ Function in Cardiovascular Protection and Neovascularization Implies That They Might Be Used to Treat Ischemia and Atherosclerotic Cardiovascular Diseases.” <https://doi.org/10.31219/osf.io/2h8c7>.
92. Moataz Dowaidar. 2021ba. “Ferropsis Cell Death Can Cause Complications That May Be Difficult to Detect and Quantify: Autophagy Role and Possible Therapeutics.” <https://doi.org/10.31219/osf.io/zd2jg>.

93. Moataz Dowaidar. 2021bb. "Following the Discovery of Anti-MDA5 Ab, the Clinical Understanding of Dermatomyositis Has Been Improved." <https://doi.org/10.31219/osf.io/j2t5f>.
94. Moataz Dowaidar. 2021bc. "For the Treatment of Cystic Fibrosis, RNA Medicines, Gene Transfer Therapies, and Gene Editing Treatments Have Potential." <https://doi.org/10.31219/osf.io/6afzm>.
95. Moataz Dowaidar. 2021bd. "Frontotemporal Dementia Is a Complex Disorder with a Wide Spectrum of Clinical Symptoms. Personalized Medicine and Gene Therapy Are Promising Strategies for Treatment." <https://doi.org/10.31219/osf.io/gh4x7>.
96. Moataz Dowaidar. 2021be. "G6PD Deficiency Is a Common Genetic Trait That Can Protect Heterozygotes from Dying from Malaria." <https://doi.org/10.31219/osf.io/g2kza>.
97. Moataz Dowaidar. 2021bf. "Gastric Cancer Is the World's Second-Largest Death Cause. Peptides Can Be Used to Deliver Radiation or Other Fatal Chemicals to Tumors." <https://doi.org/10.31219/osf.io/eu5mj>.
98. Moataz Dowaidar. 2021bg. "Gene Doping May Be Possible for Lifestyle Enhancement." <https://doi.org/10.31219/osf.io/8xkm5>.
99. Moataz Dowaidar. 2021bh. "Gene Expression Assays Gather Evidence That They Can Provide Useful Therapeutic Information in Young Women." <https://doi.org/10.31219/osf.io/d372s>.
100. Moataz Dowaidar. 2021bi. "Gene Therapy and Genome-Editing Treatments That Can Protect Patients from Coronary Artery Disease Are under Investigation." <https://doi.org/10.31219/osf.io/xqgf8>.
101. Moataz Dowaidar. 2021bj. "Gene Therapy Approaches for Hemophilia A and B." <https://doi.org/10.31219/osf.io/ufc4g>.
102. Moataz Dowaidar. 2021bk. "Gene Therapy for the Central Nervous System Has Been Initiated. This Expansion Will Require Some Degree of Simplicity in Delivery Processes." <https://doi.org/10.31219/osf.io/hdy5q>.
103. Moataz Dowaidar. 2021bl. "Gene Therapy for the Treatment of Spinal Muscular Atrophy." <https://doi.org/10.31219/osf.io/kpz5f>.
104. Moataz Dowaidar. 2021bm. "Gene Therapy May Benefit Inherited Ichthyoses with Concurrent Fungal Infections and Severe Ichthyoidoses." <https://doi.org/10.31219/osf.io/zxmun>.
105. Moataz Dowaidar. 2021bn. "Gene Therapy May Target APOE for Alzheimer's Disease." <https://doi.org/10.31219/osf.io/3y52k>.
106. Moataz Dowaidar. 2021bo. "Gene Therapy Promises Accurate, Targeted Administration and Overcoming Drug Resistance in Diverse Cancer Cells." <https://doi.org/10.31219/osf.io/j34n6>.
107. Moataz Dowaidar. 2021bp. "Gene Therapy Targeting FVIII, FIX for Haemophilia Treatment." <https://doi.org/10.31219/osf.io/qcbwp>.
108. Moataz Dowaidar. 2021bq. "Gene Therapy Targeting PRMT5 May Be Useful in Immunotherapy." <https://doi.org/10.31219/osf.io/gkw8j>.

109. Moataz Dowaidar. 2021br. "Gene Therapy Using Extracellular Vesicles Loaded with miRNA Derived from Bone Marrow Mesenchymal Stem Cells Is a Cell-Free Medication Delivery Method Used in a Variety of Diseases." <https://doi.org/10.31219/osf.io/3znvw>.
110. Moataz Dowaidar. 2021bs. "Genetic Engineered MSCs Are Attractive Possibilities for Regenerative Stem-Cell Therapy to Treat Several Liver Diseases." <https://doi.org/10.31219/osf.io/4cfrd>.
111. Moataz Dowaidar. 2021bt. "Genetic Variants Shared between Alzheimer's Disease and Parkinson's Disease Have Been Discovered in Blood and Brain Samples. Somatic Mosaicism Might Function as an Accelerator." <https://doi.org/10.31219/osf.io/tr58n>.
112. Moataz Dowaidar. 2021bu. "Genome-Wide Association Studies Promise to Discover Novel Indicators of Hypertension. Endothelin-Related SNPs Are Currently in Clinical Trials." <https://doi.org/10.31219/osf.io/2n4wa>.
113. Moataz Dowaidar. 2021bv. "Gingival and Intraventricular Haemorrhages Are Severe Newborn Diseases Causing Damage to White Matter and Neurological Dysfunction in Surviving Newborns Who Can Benefit from Gene Therapy." <https://doi.org/10.31219/osf.io/qb84p>.
114. Moataz Dowaidar. 2021bw. "Glioblastoma Therapeutic Approaches Were Established Utilizing Contemporary Discoveries in Delivering Medicines to the Brain as Smart Nanoparticles for Focused Therapy." <https://doi.org/10.31219/osf.io/db4f6>.
115. Moataz Dowaidar. 2021bx. "Haemophilia Gene Therapy Is in Clinical Studies, Making Continuous Safety and Efficacy Testing a Key Emphasis." <https://doi.org/10.31219/osf.io/sa8ny>.
116. Moataz Dowaidar. 2021by. "Hematopoietic Stem Cell Transplantation and Gene Therapy Are the Sole Treatments for Sickle Cell Disease and Other Hemoglobinopathies." <https://doi.org/10.31219/osf.io/v8xqc>.
117. Moataz Dowaidar. 2021bz. "Huntington's Disease Gene Therapy and Nanomedicines May Be Available Shortly." <https://doi.org/10.31219/osf.io/rxvgd>.
118. Moataz Dowaidar. 2021ca. "Hybrid Gene Therapy Designed to Fully Understand the Underlying Molecular Cancer Process May Be a Feasible Option." <https://doi.org/10.31219/osf.io/ajyfd>.
119. Moataz Dowaidar. 2021cb. "Hydrogels Are Promising Considering Their Incredible Capacity to Modify, Encapsulate and Co-Deliver Medicinal Compounds, Cells, Biomolecules, and Nanomaterials." <https://doi.org/10.31219/osf.io/px3qy>.
120. Moataz Dowaidar. 2021cc. "Immune Evasion Is Linked to Histone Variation Malfunction. Gene Therapy Could Provide Tools for Targeting Histone Variant Deposition as a Critical Part of Its Pharmacology." <https://doi.org/10.31219/osf.io/kjm76>.
121. Moataz Dowaidar. 2021cd. "Implementing the Human Artificial Chromosome Gene Therapy Platform Remains Challenging, but Continuous Animal Model Research Will Advance the Platform Closer to Clinical Trials." <https://doi.org/10.31219/osf.io/a53f7>.
122. Moataz Dowaidar. 2021ce. "Inflammatory Breast Cancer Remains the Most Aggressive Form of Breast Cancer. A Multimodality Therapeutic Plan Has Shown Improved Survival Results." <https://doi.org/10.31219/osf.io/cr935>.

123. Moataz Dowaidar. 2021cf. “Inherited Immunohematological and Metabolic Diseases Have the Potential to Improve Significantly, or Be Cured, Using Haematopoietic Stem Cell Transplantation Gene Therapy.” <https://doi.org/10.31219/osf.io/ukbnm>.
124. Moataz Dowaidar. 2021cg. “Insulin and IGF-1 Receptors Mutations Can Lead to Targets for Gene Therapy in Diabetes, Obesity, and Metabolic Syndrome.” <https://doi.org/10.31219/osf.io/s86x5>.
125. Moataz Dowaidar. 2021ch. “Integrating High-Throughput Genetics and Neuroimaging Technologies Promises Greater Information on Neurobiological Anomalies in Neurodegenerative Diseases.” <https://doi.org/10.31219/osf.io/hpgyz>.
126. Moataz Dowaidar. 2021ci. “Intravitreal and Subretinal Injections Currently Deliver Most Gene Therapy, Including siRNA for Eye Illnesses. Non-Viral Vectors May Provide Targeting.” <https://doi.org/10.31219/osf.io/rjkhy>.
127. Moataz Dowaidar. 2021cj. “LncRNA Regulating Reprogramming Glucose Metabolism Has Become One of the Most Tempting Antineoplastic Targets for Gene Therapy.” <https://doi.org/10.31219/osf.io/hqma5>.
128. Moataz Dowaidar. 2021ck. “lncRNAs Are Upregulated and Downregulated in OS Cells. Angiogenesis, Metastasis, Cell Signaling, Autophagy, and Death Are among Biological Processes That RNAs Play a Role in.” <https://doi.org/10.31219/osf.io/48n7q>.
129. Moataz Dowaidar. 2021cl. “Magnetic Nanoparticles Are Widely Used in Drug Delivery, Imaging, Diagnosis, and Targeting. It Has Promises for the Treatment of Inflammatory Disorders such as Rheumatoid Arthritis.” <https://doi.org/10.31219/osf.io/p2gme>.
130. Moataz Dowaidar. 2021cm. “Many miRNAs Participate in Inflammatory Regulation and Bone Metabolism. Overexpression of miR21 and miR155 Releases Proinflammatory Cytokines.” <https://doi.org/10.31219/osf.io/2wuvp>.
131. Moataz Dowaidar. 2021cn. “MiR490’s Diagnostic Capacity Was Demonstrated in Various Cancer Kinds and Diseases, Adding to Its Clinical Value.” <https://doi.org/10.31219/osf.io/wysre>.
132. Moataz Dowaidar. 2021co. “miRNAs Have an Impact on Xeno-Infectious Diseases by Influencing Host And/or Infection Factors.” <https://doi.org/10.31219/osf.io/7qewx>.
133. Moataz Dowaidar. 2021cp. “Mutations in MED12 Lead to Mental Retardation, Including Opitz–Kaveggia Syndrome, Ohdo Syndrome, Lujan–Fryns Syndrome, and Psychosis. It’s a Target for Gene Therapy.” <https://doi.org/10.31219/osf.io/cyns8>.
134. Moataz Dowaidar. 2021cq. “Nanocarriers Can Be Used to Control the Activity of Genome Editing in a Spatiotemporal Way by Using Stimulusresponsive Nanocarriers.” <https://doi.org/10.31219/osf.io/nua89>.
135. Moataz Dowaidar. 2021cr. “Nanomaterials Were Formed into Various Shapes, with Functionalization Aimed at Various Internalization Processes. Their Nanoscale Size Allows Drugs to Reach Cells or Extracellular Environments.” <https://doi.org/10.31219/osf.io/p2ajv>.
136. Moataz Dowaidar. 2021cs. “Nanomedicine Is Offering Promising Strategies for Tumor Blockade Treatment.” <https://doi.org/10.31219/osf.io/yzxuq>.

137. Moataz Dowaidar. 2021ct. "Network Medicine Might Lead to New Treatments for Dyslipidemia. It Will Be a Challenging Method to Implement in a Clinical Context." <https://doi.org/10.31219/osf.io/nksbw>.
138. Moataz Dowaidar. 2021cu. "Neuroinflammation Caused by Activated Microglia and Astrocytes Can Contribute to the Progression of Pathogenic Damage to Substantia Nigra Neurons, Playing a Role in Parkinson's Disease Progression." <https://doi.org/10.31219/osf.io/ac896>.
139. Moataz Dowaidar. 2021cv. "Neurologists Rarely Perform Genetic Testing for Parkinson's Disease. Evidence Suggests That Many Patients with Major Genetic Variants Go Undiagnosed." <https://doi.org/10.31219/osf.io/ykpb2>.
140. Moataz Dowaidar. 2021cw. "Neuronal Intranuclear Hyaline Inclusion Disease Is a Neurodegenerative Condition Which Can Be a Target for Gene Therapy." <https://doi.org/10.31219/osf.io/upgqd>.
141. Moataz Dowaidar. 2021cx. "New Therapies Aim at Restoring the Molecular, Morphological, and Functional Integrity of Parkinson's Specific Brain Circuits." <https://doi.org/10.31219/osf.io/dvyxc>.
142. Moataz Dowaidar. 2021cy. "Not All lncMIRHG's Are 'Junk Transcripts,'. LncM IRHG Loci May Make Both Functional miRNAs and lncRNAs, Which Can Work Together or Separately." <https://doi.org/10.31219/osf.io/a567w>.
143. Moataz Dowaidar. 2021cz. "Nrf2 Signaling Pathways Are Part of a Wider Network of Signaling Pathways Regulating Thymoquinone Therapeutic Actions Which Need Innovative Formulations and Delivery Methods." <https://doi.org/10.31219/osf.io/u2fa7>.
144. Moataz Dowaidar. 2021da. "Omics Should Be Integrated with Genomics to Uncover Molecular Networks and Tissue and Single-Cell Epigenetic Changes. With These Findings, Targeted Pseudoexfoliation Syndrome and Glaucoma Gene Therapy Procedures May Be Viable." <https://doi.org/10.31219/osf.io/48fj5>.
145. Moataz Dowaidar. 2021db. "Ophthalmic Gene and Cell Therapies." <https://doi.org/10.31219/osf.io/n84m9>.
146. Moataz Dowaidar. 2021dc. "P21 Is a Flexible, Multi-Functional Protein. It Governs Various Tumor Cell Activities, Including Autophagy. p21 Is a Possible Radiotherapy Target." <https://doi.org/10.31219/osf.io/ydkca>.
147. Moataz Dowaidar. 2021dd. "Parkinson's Disease Simulating Complexity via Improving the Identification of Significant Genetic Alterations and Environmental Contaminants Should Be a Priority." <https://doi.org/10.31219/osf.io/pmcu9>.
148. Moataz Dowaidar. 2021de. "Patient-Specific Microphysiology Systems Are Likely to Become a Crucial Aspect of Translational Research and Precision Medicine." <https://doi.org/10.31219/osf.io/bc8fr>.
149. Moataz Dowaidar. 2021df. "Patients with PMD Who Are Thoroughly Screened by Genomic Medicine Have a Considerable Chance of Benefiting Greatly from Whole-Genome Sequencing." <https://doi.org/10.31219/osf.io/dajft>.
150. Moataz Dowaidar. 2021dg. "Polydopamine Nanoparticles' Activity and Long-Term Stability Should Be Fully Studied for Gene Therapy Applications." <https://doi.org/10.31219/osf.io/x4nej>.

151. Moataz Dowaidar. 2021dh. "Potential Therapeutics for Primary Mitochondrial Disorders." <https://doi.org/10.31219/osf.io/6pz5k>.
152. Moataz Dowaidar. 2021di. "Potentials of Medicinal Nanostructured Diamond Particles and Coatings." <https://doi.org/10.31219/osf.io/h68xz>.
153. Moataz Dowaidar. 2021dj. "Preclinical Investigations Revealed Possibilities for Salmonella Tumor Treatment. Bacteria Can Also Be Coupled to Nanomaterials Enabling Drug-Loading, Photocatalytic And/or Magnetic Properties, Using the Bacteria's Net Negative Charge." <https://doi.org/10.31219/osf.io/embqk>.
154. Moataz Dowaidar. 2021dk. "Research into P2X Purinergic Receptor Function in Tumor Growth Has Made Substantial Progress with Potential Gene Therapy Targeting." <https://doi.org/10.31219/osf.io/r34fs>.
155. Moataz Dowaidar. 2021dl. "RNA Therapies Hold Great Promise for Treating Cancer. High-Throughput Screening Techniques Have Facilitated the Development of RNA Treatments." <https://doi.org/10.31219/osf.io/9vxrb>.
156. Moataz Dowaidar. 2021dm. "RNAi Treatment Has Been Shown to Successfully Modify Human-Related Target Gene Expression, Including Cancer. It Has the Capacity to Control Non-Standard Oncogenes, such as Oncogenic lncRNAs." <https://doi.org/10.31219/osf.io/bwqep>.
157. Moataz Dowaidar. 2021dn. "RNAs Hold a Lot of Potential When It Comes to Druggable Molecular Targets." <https://doi.org/10.31219/osf.io/2dtxg>.
158. Moataz Dowaidar. 2021do. "Shadow Enhancers' Objective Seems to Be to Establish Robust Growth Patterns Independent of Genetic or Environmental Stress." <https://doi.org/10.31219/osf.io/qfnkp>.
159. Moataz Dowaidar. 2021dp. "Sickle Cell Disease Hematopoietic Stem Cell Gene Therapy with Globin Gene Addition Is Promising." <https://doi.org/10.31219/osf.io/j5fkb>.
160. Moataz Dowaidar. 2021dq. "Single-Gene Mutations in mtDNA-Associated Proteins Are Unlikely to Be the Main Cause of Sporadic Parkinson's Disease. Cumulative Genetic Variation in Numerous Genes May Be Important in Neurodegeneration and PD Risk." <https://doi.org/10.31219/osf.io/89qte>.
161. Moataz Dowaidar. 2021dr. "Small Nuclear Ribonucleoproteins (snRNPs) Based Gene Therapy." <https://doi.org/10.31219/osf.io/c43r9>.
162. Moataz Dowaidar. 2021ds. "Studying the Pathologic Mechanisms of Osteoporosis and the Bone Microenvironment May Help Researchers Better Know the Etiology of Rheumatoid Arthritis, Periodontitis, and Multiple Myeloma, as Well as Other Inflammatory and Autoimmune Disorders." <https://doi.org/10.31219/osf.io/t3z6y>.
163. Moataz Dowaidar. 2021dt. "Suicide Gene Therapy May Be Effective in the Treatment of Malignant Glioma." <https://doi.org/10.31219/osf.io/vdkst>.
164. Moataz Dowaidar. 2021du. "Synuclein Is a Protein That Is Expressed in Brain Tissue. The Specific Missense Mutation (SNCA) Found in a Family with Parkinson's Disease Is the Cause. Other Diseases Include Alzheimer's Disease and REM Sleep Behavior Disorder." <https://doi.org/10.31219/osf.io/bs8rc>.



165. Moataz Dowaidar. 2021dv. "Systems Biology Is a Method for Analyzing Massive Amounts of Multidimensional Data Generated by Omics Technologies. Cross-Validation of the Various Technological Platforms Is Critical." <https://doi.org/10.31219/osf.io/p8vkd>.
166. Moataz Dowaidar. 2021dw. "Targeting Mitochondria and Especially Taz Gene Mutation Induces CL May Give Novel Therapeutic Alternatives for Treating Barth Syndrome." <https://doi.org/10.31219/osf.io/unfpy>.
167. Moataz Dowaidar. 2021dx. "The Ability to Combine Multiple mRNA Antigens Targeting Multiple Pathogens Simultaneously, and the Robust Immune Responses Are Confirmed in Several Clinical Studies." <https://doi.org/10.31219/osf.io/6qksx>.
168. Moataz Dowaidar. 2021dy. "The Cubic Polyhedral Oligomeric Silsesquioxanes Based Hybrid Materials Have a Wide Variety of Applications, Including Drug Administration, Gene Therapy, Biological Imaging, and Bone Regeneration." <https://doi.org/10.31219/osf.io/9peq8>.
169. Moataz Dowaidar. 2021dz. "The Development of Tissue Replacement Therapies and Drug Discovery Was a Critical Milestone in Advancing Regenerative Medicine." <https://doi.org/10.31219/osf.io/w9bsm>.
170. Moataz Dowaidar. 2021ea. "The Epidemic of COVID-19 Prompted Widespread Use of mRNA Vaccinations." <https://doi.org/10.31219/osf.io/jqws5>.
171. Moataz Dowaidar. 2021eb. "The Most Useful and Commonly Available Acute Rejection Surveillance Strategies Are Routine Monitoring of Myocardial Function and Donor-Specific Anti-HLA Abs Monitoring." <https://doi.org/10.31219/osf.io/ebw68>.
172. Moataz Dowaidar. 2021ec. "The Protease MBTPS2 Is an Important Regulator of Several Cellular Processes, Especially in Health and Sickness." <https://doi.org/10.31219/osf.io/qyn6h>.
173. Moataz Dowaidar. 2021ed. "The Sigma 1 Receptor (S1R) Is a Potential Therapeutic Target for the Treatment of Huntington's Disease." <https://doi.org/10.31219/osf.io/mcefx>.
174. Moataz Dowaidar. 2021ee. "The Use of a Network Medicine Approach Might Result in Innovative Strategies for Lowering Coronary Heart Disease and CV Risks." <https://doi.org/10.31219/osf.io/eakg8>.
175. Moataz Dowaidar. 2021ef. "The Vasoconstrictor Endothelin System Involvement in Chronic Kidney Diseases Pathogenesis Is Now the Most Often Employed Treatment Method." <https://doi.org/10.31219/osf.io/cnkqy>.
176. Moataz Dowaidar. 2021eg. "The VPS35-D620N Mutation Is Associated with Parkinson's Disease and Can Be a Target for Gene Therapy." <https://doi.org/10.31219/osf.io/83sxx>.
177. Moataz Dowaidar. 2021eh. "Therapeutics Including Gene Therapy for Osteoarthritis as a Concept." <https://doi.org/10.31219/osf.io/7zsqy>.
178. Moataz Dowaidar. 2021ei. "Tissue Hypoxia Has Been Established as a Master Regulator for Alternative Splicing, with Substantial Clinical Consequences and Possibilities for Gene Therapy Targeting." <https://doi.org/10.31219/osf.io/5pbw4>.

179. Moataz Dowaidar. 2021ej. “To Rectify Alzheimer’s Disease Etiology, Excessive Mitochondrial Division Might Be Stopped or Mitophagy Might Be Promoted.” <https://doi.org/10.31219/osf.io/6kdxw>.
180. Moataz Dowaidar. 2021ek. “Transcriptomics Is a Rapidly Growing Field That Generates New Data That May Be Used on Its Own or in Combination with Existing Clinical Data for Development of New Therapeutics, Including Gene Therapy.” <https://doi.org/10.31219/osf.io/kfr6a>.
181. Moataz Dowaidar. 2021el. “Tumor Microenvironment Has Clinical Significance in Terms of Prognosis and Therapy Prediction.” <https://doi.org/10.31219/osf.io/4dz8q>.
182. Moataz Dowaidar. 2021em. “Using AAV as a Gene Delivery Vector in the Neural System Is Effective in Several Animals, such as Nonhuman Primates.” <https://doi.org/10.31219/osf.io/ut4fa>.
183. Moataz Dowaidar. 2021en. “Using Pre-Existing Datasets to Combine Published Information with New Metrics Would Help Researchers Construct a Broader Picture of Chromatin in Disease.” <https://doi.org/10.31219/osf.io/gsqv5>.
184. Moataz Dowaidar. 2021eo. “Virus-like Particles Are Good Nanocarriers for Liquid Biopsy Probes, Imaging Contrast Agents, and Anticancer Medications.” <https://doi.org/10.31219/osf.io/xbtka>.
185. Moataz Dowaidar. 2021ep. “ZEB1 Controls the Expression of ICAM1, Promoting Monocyte-Macrophage Adhesion and Hence the Formation of Atherosclerotic Lesions.” <https://doi.org/10.31219/osf.io/kzjqg>.
186. Moataz Dowaidar. 2021eq. “Gene Therapy Development and Legislation.” <https://doi.org/10.31219/osf.io/mwb2n>.
187. Moataz Dowaidar. 2021er. “Next-Generation Sequencing Is Now Utilized to Identify Genetic Abnormalities and Develop Gene Therapy.” <https://doi.org/10.31219/osf.io/em7xp>.
188. Moataz Dowaidar. 2021es. “Nucleic Acid Designs, Artificial Intelligence for Screening Nanomaterials, and Enhanced Characterization Methods Are Needed to Make Nanomedicine More Successful.” <https://doi.org/10.31219/osf.io/2w5aq>.
189. Moataz Dowaidar. 2021et. “Potential Strategies for Cancer Gene Therapy.” <https://doi.org/10.31219/osf.io/atcqz>.
190. Moataz Dowaidar. 2021eu. “Quantitative Groups Will Be Critical to the Success of Future Gene Therapy Programs.” <https://doi.org/10.31219/osf.io/v97ht>.
191. Moataz Dowaidar. 2021ev. “The Treatment of Major Human Illnesses with Recombinant Adeno-Associated Virus (rAAV) Has Shown Tremendous Promises.” <https://doi.org/10.31219/osf.io/uwa4e>.
192. Moataz Dowaidar. 2021ew. “Carbon Nanotubes Have Enormous Potential in Gene Therapy.” <https://doi.org/10.31219/osf.io/9bcxk>.
193. Moataz Dowaidar. 2021ex. “Charge-Alteration-Based Approaches Can Address the Evolving Needs of Nucleic Acid-Based Gene Therapy, Charge Reversal Techniques Are Also Promising.” <https://doi.org/10.31219/osf.io/zwq5h>.
194. Moataz Dowaidar. 2021ey. “Chromosome X, the Most Explored Genome-Editing Chromosome, Presents Possibilities for Hemophilia A Treatments.” <https://doi.org/10.31219/osf.io/6vsdz>.

195. Moataz Dowaidar. 2021ez. “Clinical Investigations Show That siRNA May Be Used to Treat a Variety of Disorders, Including Cancer.” <https://doi.org/10.31219/osf.io/fcsgq>.
196. Moataz Dowaidar. 2021fa. “Cyclodextrins as Potential Gene Therapy Vectors.” <https://doi.org/10.31219/osf.io/zhtsc>.
197. Moataz Dowaidar. 2021fb. “Development of Specialized Carriers Capable of Delivering Effective RNAi and siRNA Gene Therapy.” <https://doi.org/10.31219/osf.io/3ykwm>.
198. Moataz Dowaidar. 2021fc. “Gene Therapy Can Target Mutations such as BRAF, Which Have Been Shown to Make Tumors More Susceptible to Autophagy Suppression.” <https://doi.org/10.31219/osf.io/3gwra>.
199. Moataz Dowaidar. 2021fd. “Gene Therapy Vectors Should Enable CRISPR Systems to Accumulate at Disease Sites and Successfully Penetrate Nuclei.” <https://doi.org/10.31219/osf.io/xzmmc>.
200. Moataz Dowaidar. 2021fe. “Nanoformulations Can Be Utilized to Deliver Effective siRNA to Tumor Cells to Decrease Gene Expression.” <https://doi.org/10.31219/osf.io/zvukc>.
201. Moataz Dowaidar. 2021ff. “Neuronal Ceroid Lipofuscinosis Therapeutics.” <https://doi.org/10.31219/osf.io/75vcp>.
202. Moataz Dowaidar. 2021fg. “Nonviral Gene Delivery Vectors for Transfection of the CAR Gene for CAR-T Cell Therapy.” <https://doi.org/10.31219/osf.io/ckxh5>.
203. Moataz Dowaidar. 2021fh. “Potential HIV Gene Therapy Strategies.” <https://doi.org/10.31219/osf.io/e5hm2>.
204. Moataz Dowaidar. 2021fi. “Research on Cell Sources for Brain Cell Replacement Methods Has Gained Major Importance. Cell and Gene Therapy Are Potentially Intriguing New Domains of Regenerative Medicine.” <https://doi.org/10.31219/osf.io/g835b>.
205. Moataz Dowaidar. 2021fj. “RNAi-Based Gene Therapy Provides a Wide Variety of Applications. Safe, Biodegradable Nano Delivery Vectors Are Still Needed.” <https://doi.org/10.31219/osf.io/s2zhn>.
206. Moataz Dowaidar. 2021fk. “Strategies for Treating Multiple Sclerosis with Gene Therapy.” <https://doi.org/10.31219/osf.io/sycn6>.
207. Moataz Dowaidar. 2021fl. “The Combination of Unique Biomolecules and Nanoparticles Has Shown Successful Gene Therapy Treatment Approaches for Non-Small Cell Lung Cancer Treatment.” <https://doi.org/10.31219/osf.io/yeq5z>.
208. Moataz Dowaidar. 2021fm. “Understanding Why the Same Gene Delivery Vector Behaves Differently in Different Cell Types Is Essential for Developing More Adaptable Transfection Systems.” <https://doi.org/10.31219/osf.io/6q8af>.
209. Moataz Dowaidar. 2021fn. “AAV9 Is Considered the Most Efficient AAV Serotype Targeting Blood-Brain Barriers. To Enhance Effective Gene Therapy for CNS Illnesses, Testing Novel Vectors with More Efficient Crossing Capabilities Is Vital.” <https://doi.org/10.31219/osf.io/7bf5s>.
210. Moataz Dowaidar. 2021fo. “Artificial miRNAs Are Potential Gene Therapy Tools, Especially for Incurable Monogenic Disorders.” <https://doi.org/10.31219/osf.io/d5nm>.

211. Moataz Dowaidar. 2021fp. “Breakthroughs in mRNA Modification and Nanoparticle-Based Delivery Vehicles Facilitate Gene Therapy Strategies.” <https://doi.org/10.31219/osf.io/ky7dt>.
212. Moataz Dowaidar. 2021fq. “CRISPR/Cas9-Mediated Genome Editing Has Demonstrated Significant Promise for Genetic Correction in Autologous Hematopoietic Stem/progenitor Cells (HSPCs) and Induced Pluripotent Stem Cells (iPSCs).” <https://doi.org/10.31219/osf.io/xk54r>.
213. Moataz Dowaidar. 2021fr. “Gene Therapy Vectors for Targeting the Heart.” <https://doi.org/10.31219/osf.io/gcbhf>.
214. Moataz Dowaidar. 2021fs. “Liposomes Can Minimize Cardiotoxicity, Address Drug Resistance, and Improve Overall Drug Release Profiles in Breast Cancer.” <https://doi.org/10.31219/osf.io/tn56d>.
215. Moataz Dowaidar. 2021ft. “Liposomes with Cerasome-Forming Lipids as Gene Therapy Vectors.” <https://doi.org/10.31219/osf.io/zjn6v>.
216. Moataz Dowaidar. 2021fu. “Nanomaterials Combine Multiple Therapeutic Approaches for Cancer Cell Multidrug Resistance, Ferroptotic Cell Death Is Promising in Various Cancers.” <https://doi.org/10.31219/osf.io/7bg9t>.
217. Moataz Dowaidar. 2021fv. “Nanomedicines for Enhanced Permeability and Retention (EPR)-Stratified Patients Have the Potential to Improve Treatment Outcomes.” <https://doi.org/10.31219/osf.io/xrcb2>.
218. Moataz Dowaidar. 2021fw. “RNA-Based Gene Therapy for Manipulating the Neuroinflammatory Cascade Closely Linked to Neurodegeneration Can Help Reduce Disease Development.” <https://doi.org/10.31219/osf.io/2hswv>.
219. Moataz Dowaidar. 2021fx. “Targeted Chemical Nucleases Have a Wide Range of Untapped Applications in Biological Fields, Including Gene Therapy.” <https://doi.org/10.31219/osf.io/6bexs>.
220. Moataz Dowaidar. 2021fy. “Bacterial Nanoparticles Can Deliver Proteins, Medications, Enzymes, and Genes to Diagnose and Cure Numerous Illnesses.” <https://doi.org/10.31219/osf.io/7gyna>.
221. Moataz Dowaidar. 2021fz. “Exosomal miRNA Diagnostic and Gene Therapy Tools.” <https://doi.org/10.31219/osf.io/aknrc>.
222. Moataz Dowaidar. 2021ga. “Gene Modification Research Has Potential, from Diagnostic to Therapeutic Levels. The Most Promising Metabolic Pathways Include the TGF-1 Signaling System, Inflammation and Protein Transport.” <https://doi.org/10.31219/osf.io/5ert4>.
223. Moataz Dowaidar. 2021gb. “Gene Therapy Using MnO<sub>2</sub> Nanoparticles.” <https://doi.org/10.31219/osf.io/xmwjs>.
224. Moataz Dowaidar. 2021gc. “Gene-Regulatory Elements May Change the Amount, Timing, or Location of Gene Expression, Cis-Regulation Therapy Platforms Might Become a Gene Therapy to Treat Many Genetic Diseases.” <https://doi.org/10.31219/osf.io/xc5a2>.
225. Moataz Dowaidar. 2021gd. “Hemophilia Therapeutics.” <https://doi.org/10.31219/osf.io/gu74x>.

226. Moataz Dowaidar. 2021ge. “Mesenchymal Stem Cells Strategies in Cancer Immunotherapy.” <https://doi.org/10.31219/osf.io/dkv6w>.
227. Moataz Dowaidar. 2021gf. “Nanomaterials Can Inhibit Planktonic and Biofilm Bacteria and Can Be Used as Topical Therapy for Mouth and Wound-Related Infections.” <https://doi.org/10.31219/osf.io/aqd2e>.
228. Moataz Dowaidar. 2021gg. “New Technologies to Improve CAR T Cell Generation and Biomanufacturing Will Lead to Safer, More Therapeutically Effective Cells.” <https://doi.org/10.31219/osf.io/un8gp>.
229. Moataz Dowaidar. 2021gh. “Ocular Gene Therapy Strategies.” <https://doi.org/10.31219/osf.io/7en3k>.
230. Moataz Dowaidar. 2021gi. “Peripheral Nerve Injury Therapeutics, Including Electrical Stimulation, Stem Cell Treatments, and Synthetic Neural Scaffolds, Have Shown Promising Preclinical and Even Clinical Results with Potential Regenerative Treatment.” <https://doi.org/10.31219/osf.io/m8cs9>.
231. Moataz Dowaidar. 2021gj. “Photothermal and Photodynamic Photoactivation of Nanomaterials-Based Prodrugs Are Two Key Methods for NIR Light-Mediated Photoactivation.” <https://doi.org/10.31219/osf.io/2bh3r>.
232. Moataz Dowaidar. 2021gk. “Quantum Dots Have the Potential to Be Used in Gene Therapy.” <https://doi.org/10.31219/osf.io/bdeg6>.
233. Moataz Dowaidar. 2021gl. “Sickle Cell Disease Has Emerged as a Public Health Concern. Some Drugs May Conflict with Curative Therapies, yet They May Be Useful as a Bridge to HSCT and Gene Therapy.” <https://doi.org/10.31219/osf.io/6kufh>.
234. Moataz Dowaidar. 2021gm. “Stimulator of Interferon Genes (STING)-Activating Nanoparticles Can Be Employed as a Tool for Controlled Immune Activation.” <https://doi.org/10.31219/osf.io/2ez7a>.
235. Moataz Dowaidar. 2021gn. “CRISPR/Cas9 Has Introduced New Gene Therapy Possibilities for Muscular Dystrophies.” <https://doi.org/10.31219/osf.io/ug8v4>.
236. Moataz Dowaidar. 2021go. “Degradable Branched Polycationic Systems Are Promising Gene Therapy Vectors.” <https://doi.org/10.31219/osf.io/utypf>.
237. Moataz Dowaidar. 2021gp. “Developing Nanotechnology Platforms for Peptide-Based Combinatory Cancer Gene Therapy Will Likely Have a Significant Influence on the Development of Personalized Cancer Medicines.” <https://doi.org/10.31219/osf.io/zbrkj>.
238. Moataz Dowaidar. 2021gq. “Exosomes May Prevent Cardiac Attacks, Heart Failure, and Cardiomyopathy.” <https://doi.org/10.31219/osf.io/agm3k>.
239. Moataz Dowaidar. 2021gr. “Exosomes Potential Therapeutics.” <https://doi.org/10.31219/osf.io/mhwt3>.
240. Moataz Dowaidar. 2021gs. “Gene Therapy Using miRNA Treatment Suppresses the Expression of Bone-Forming Defective Genes and Raises the Expression of Genes That Become Dormant during Bone Building.” <https://doi.org/10.31219/osf.io/tcka3>.
241. Moataz Dowaidar. 2021gt. “Genome-Editing Is Promising for Producing Therapeutically Relevant Animal Models for Possible Therapies for Rare Human Diseases.” <https://doi.org/10.31219/osf.io/dehr9>.

242. Moataz Dowaidar. 2021gu. “Human Corneal Endothelial Cells Grafts to Replace Cadaveric Donor Corneas.” <https://doi.org/10.31219/osf.io/p9x7e>.
243. Moataz Dowaidar. 2021gv. “Hybrid Nanotechnology and Peptide Nucleic Acid Could Improve the Effectiveness of Gene Therapy by Increasing Its Cell Permeability.” <https://doi.org/10.31219/osf.io/d8wzt>.
244. Moataz Dowaidar. 2021gw. “In Prenatal Stem Cell Transplantation and in Utero Gene Therapy, a Wide Spectrum of Genetic Diseases Can Be Diagnosed and Treated before Birth.” <https://doi.org/10.31219/osf.io/sa3vz>.
245. Moataz Dowaidar. 2021gx. “Magnetic Iron Oxide Nanoparticles Have Potential on Gene Therapy Effectiveness and Biocompatibility.” <https://doi.org/10.31219/osf.io/f3hm4>.
246. Moataz Dowaidar. 2021gy. “Neurotrophin Gene Therapy May Be Able to Treat Individuals with Noise-Induced Hearing Loss or Neural Presbycusis.” <https://doi.org/10.31219/osf.io/spkxh>.
247. Moataz Dowaidar. 2021gz. “Plant Viral Nanoparticles Can Be Used in Biological Systems for Loading and Transporting Cargo.” <https://doi.org/10.31219/osf.io/txdka>.
248. Moataz Dowaidar. 2021ha. “Polydopamine May Be Easily Functionalized with a Range of Nanomaterials for Synergistic Cancer Therapy, in Addition to Its Exceptional Photothermal Effects.” <https://doi.org/10.31219/osf.io/cq942>.
249. Moataz Dowaidar. 2021hb. “Tumor-Targeted Drug Delivery Systems for Anticancer Therapies Can Selectively Provide an Appropriate Cytotoxic Payload to Cancer Cells, Reducing the Side Effects of Chemo.” <https://doi.org/10.31219/osf.io/683nj>.
250. Moataz Dowaidar. n.d. “Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy (4th Edition).”
251. Dowaidar, Moataz, Hani Nasser Abdelhamid, Mattias Hällbrink, Krista Freimann, Kaido Kurrikoff, Xiaodong Zou, and Ülo Langel. 2017. “Magnetic Nanoparticle Assisted Self-Assembly of Cell Penetrating Peptides-Oligonucleotides Complexes for Gene Delivery.” *Scientific Reports* 7 (1): 9159. <https://doi.org/10.1038/s41598-017-09803-z>.
252. Dowaidar, Moataz, Hani Nasser Abdelhamid, Mattias Hällbrink, Ülo Langel, and Xiaodong Zou. 2018. “Supplemental Material for Chitosan Enhances Gene Delivery of Oligonucleotide Complexes with Magnetic Nanoparticles–cell-Penetrating Peptide.” SAGE Journals. <https://doi.org/10.25384/SAGE.7105436.V1>.
253. Dowaidar, Moataz, Hani Nasser Abdelhamid, Mattias Hällbrink, Xiaodong Zou, and Ülo Langel. 2017a. “Graphene Oxide Nanosheets in Complex with Cell Penetrating Peptides for Oligonucleotides Delivery General Subjects.” *Biochimica et Biophysica Acta, General Subjects*. <https://pubag.nal.usda.gov/catalog/5734174>.
254. Moataz Dowaidar. 2017b. “Graphene Oxide Nanosheets in Complex with Cell Penetrating Peptides for Oligonucleotides Delivery.” *Biochimica et Biophysica Acta, General Subjects* 1861 (9): 2334–41. <https://doi.org/10.1016/j.bbagen.2017.07.002>.
255. Dowaidar, Moataz, and Moataz Dowaidar. 2018. “Chimeric Gene Delivery Vectors : Design, Synthesis, and Mechanisms from Transcriptomics Analysis.”

256. Moataz Dowaidar. 2021a. “Addiction Biology Research on miRNAs, and Their Role in the Pathophysiology of Addiction Is Enabling Gene Therapy Opportunities.” <https://doi.org/10.31219/osf.io/z5wyt>.
257. Moataz Dowaidar. 2021b. “Aptamers Targeting Vascular Endothelial Growth Factor Molecular Regulation as Potential Therapists.” <https://doi.org/10.31219/osf.io/a8qpr>.
258. Moataz Dowaidar. 2021c. “Arrhythmogenic Cardiomyopathy Is a Set of Hereditary Cardiac Muscle Disorders Where Various Etiologies Converge. Most ACM Patients Do Not Have a Genetic Diagnosis.” <https://doi.org/10.31219/osf.io/pzvtv3>.
259. Moataz Dowaidar. 2021d. “Autophagy, Immunological Response, and Inflammation All Rely on the TRIM Family Proteins. TRIM-Based Therapeutics for Inflammatory Illnesses Including Diabetes and Diabetic Comorbidities Are Promising.” <https://doi.org/10.31219/osf.io/y4g6e>.
260. Moataz Dowaidar. 2021e. “Biogenic Particles Can Be Multiantigenic, Immunostimulative and Activate Innate Immunity While Suppressing Tumor Development.” <https://doi.org/10.31219/osf.io/q2kby>.
261. Moataz Dowaidar. 2021f. “Biological Medications for Interventional Pain Have a Lot of Clinical Data behind Them. It Is Fair to Assume They Will Replace Steroid-Based Interventional Techniques, Providing Patients with Longer Relief.” <https://doi.org/10.31219/osf.io/4y5fm>.
262. Moataz Dowaidar. 2021g. “Carbon Nanofibers Assist in the Manufacture of Prosthetic Joints, Promote Tissue, Organ, Nerve Regeneration and Development, and Improve Anticancer Therapy Impact and Chemosensitization for a Range of Tumor Types.” <https://doi.org/10.31219/osf.io/z3ucn>.
263. Moataz Dowaidar. 2021h. “Emerging Therapy Options May Help Patients with RAG Deficiency, Especially Those with Severe Immune Dysregulation.” <https://doi.org/10.31219/osf.io/v5tjg>.
264. Moataz Dowaidar. 2021i. “Exosomes as Promising Gene Therapy Tools Still Need to Be Researched and Manufactured More Efficiently.” <https://doi.org/10.31219/osf.io/nw4z7>.
265. Moataz Dowaidar. 2021j. “Focus on Exosomes Could Help Make the Use of Circulating miRNA as Biomarkers More Practical. A Detailed Understanding of miRNA Behavior Should Be a Subject of Gene Therapy.” <https://doi.org/10.31219/osf.io/uan6x>.
266. Moataz Dowaidar. 2021k. “Gene-Free Viral-like Particles (VLPs) Offer a Safer Alternative to Inactivating or Weakening Viral Strains for Traditional Vaccines. VLP-Based Vaccinations without Adjuvants Have Been Found to Promote Humoral and Cellular Immunity.” <https://doi.org/10.31219/osf.io/9dvut>.
267. Moataz Dowaidar. 2021l. “Given the Importance of mTOR Signaling in a Number of Illnesses, It Looks Suitable to Use miR 99 Family Members as a Therapeutic Intervention to Deal with These Illnesses by Using Gene Therapy Tools.” <https://doi.org/10.31219/osf.io/8cwgh>.
268. Moataz Dowaidar. 2021m. “HMGB1 Has Sparked a Lot of Attention as a Model DAMP Molecule Involved in Inflammation, Inflammatory Diseases, and Cancer.” <https://doi.org/10.31219/osf.io/5qx36>.

269. Moataz Dowaidar. 2021n. “Nucleic Acid Nanocarriers Can Be Programmable, Spatially Adjustable and Biocompatible, Minimizing Systemic Toxicity and Improving Pharmacodynamics.” <https://doi.org/10.31219/osf.io/wr237>.
270. Moataz Dowaidar. 2021o. “Osteoporosis Is a Prominent Source of Morbidity and Mortality in the Elderly, Particularly in Postmenopausal Women. Long Noncoding RNAs (lncRNAs) Have Been Found to Be Important Regulators and Possible Gene Therapy Targets.” <https://doi.org/10.31219/osf.io/ghfpt>.
271. Moataz Dowaidar. 2021p. “Polycomb Genes Role in Cancer Pathophysiology Is Offering Targets for Therapeutics Including Gene Therapy.” <https://doi.org/10.31219/osf.io/sfvej>.
272. Moataz Dowaidar. 2021q. “RNA Sequencing and Microarray Analysis Are Helpful Techniques to Detect Obesity-Related lncRNAs. LncRNA Can Alter Cholesterol Metabolism and Can Be a Target for Gene Therapy.” <https://doi.org/10.31219/osf.io/3fb6w>.
273. Moataz Dowaidar. 2021r. “Sepsis-Associated Acute Kidney Damage Is a Disease That Affects the Patient’s Quality of Life. It Should Be a Target for Gene Therapy.” <https://doi.org/10.31219/osf.io/49k7q>.
274. Moataz Dowaidar. 2021s. “The Gene Expression Profiling Gives an in-Depth Insight of Breast Cancer Heterogeneity, Better than a Single Protein or Gene Expression. It Is Time to Include It in the Daily Routine.” <https://doi.org/10.31219/osf.io/xhyd7>.
275. Moataz Dowaidar. 2021t. “The Nanomedicine System Has Successfully Inhibited Tumor Neovascularization Using Gene Silencing, Chemotherapy, Photothermal Therapy, and Other Therapies.” <https://doi.org/10.31219/osf.io/rk2bf>.
276. Moataz Dowaidar. 2021u. “The Therapeutic Application of a Nucleic Acid Sequence to Patients’ Diseased Organs Is Currently Available.” <https://doi.org/10.31219/osf.io/pqsbf>.
277. Moataz Dowaidar. 2021v. “Triple-Negative Breast Cancer, Which Lacks the Expression of Hormone Receptors and HER2, Has a Worse Prognosis. Massive Parallel Sequencing Is Capable of Reliably Breaking down the Intra-Tumor and Inter-Tumor Heterogeneity.” <https://doi.org/10.31219/osf.io/pvk7u>.
278. Dowaidar, Moataz, H. A. Ismail, A. A. Alghasham, M. M. Dowaidar, and A. A. Settin. 2011. “Polymorphisms in MTHF and Ace Genes and the Association with Hypertension among Saudi Population from Qassim Region.” *Egyptian Journal of Biochemistry and Molecular Biology* 29 (1). <https://doi.org/10.4314/ejbmb.v29i1.67382>.
279. Dowaidar, Moataz, Hani Nasser Abdelhamid, Mattias Hällbrink, Ülo Langel, and Xiaodong Zou. 2018. “Chitosan Enhances Gene Delivery of Oligonucleotide Complexes with Magnetic Nanoparticles-Cell-Penetrating Peptide.” *Journal of Biomaterials Applications* 33 (3): 392–401. <https://doi.org/10.1177/0885328218796623>.
280. Dowaidar, Moataz, and Ahmad Settin. 2010. “Risk of Myocardial Infarction Related to Factor V Leiden Mutation: A Meta-Analysis.” *Genetic Testing and Molecular Biomarkers* 14 (4): 493–98. <https://doi.org/10.1089/gtmb.2010.0017>.



281. Gestin, Maxime, Moataz Dowaidar, and Ülo Langel. 2017. "Uptake Mechanism of Cell-Penetrating Peptides." *Advances in Experimental Medicine and Biology* 1030: 255–64. [https://doi.org/10.1007/978-3-319-66095-0\\_11](https://doi.org/10.1007/978-3-319-66095-0_11).
282. Ismail, H. A., A. A. Alghasham, M. M. Dowaidar, and A. A. Settin. 2011. "Polymorphisms in MTHF and Ace Genes and the Association with Hypertension among Saudi Population from Qassim Region." *Egyptian Journal of Biochemistry and Molecular Biology* 29 (1). <https://doi.org/10.4314/ejbmb.v29i1.67382>.
283. Settin, Ahmad A., Abdullah Algasham, Moataz Dowaidar, and Hisham Ismail. 2009. "Methylene Tetrahydrofolate Reductase and Angiotensin Converting Enzyme Gene Polymorphisms Related to Overweight/obesity among Saudi Subjects from Qassim Region." *Disease Markers* 27 (2): 97–102. <https://doi.org/10.3233/DMA-2009-0660>.
284. Settin, Ahmad A., Abdullah Alghasham, Ahmad Ali, Moataz Dowaidar, and Hisham Ismail. 2012. "Frequency of Thrombophilic Genetic Polymorphisms among Saudi Subjects Compared with Other Populations." *Hematology* 17 (3): 176–82. <https://doi.org/10.1179/102453312X13376952196575>.
285. Settin, Ahmad, Ibrahim S. Abu-Saif, Rizk El-Baz, Moataz Dowaidar, Rabab Abu-Al Kasim, and Shaimaa Shabana. 2007a. "Diagnosis of Sex Chromosome Disorders and Prenatal Diagnosis of Down Syndrome Using Interphase Fluorescent In-Situ Hyperidization Technique." *International Journal of Health Sciences* 1 (2): 203–9. <https://www.ncbi.nlm.nih.gov/pubmed/21475429>.
286. Settin, Ahmad, Abdullah Algasham, Moataz Dowaidar, and Hisham Ismail. 2011. "Methylene Tetrahydrofolate Reductase (MTHFR) and Angiotensinogen Converting Enzyme (ACE) Gene Polymorphisms Related to Overweight and Obesity among Saudi Patients in Al Qassim." *International Journal of Health Sciences* 5 (2 Suppl 1): 24–25. <https://www.ncbi.nlm.nih.gov/pubmed/23284565>.
287. Settin, Ahmad, Hala Almarsafawy, Ahmad Alhussieny, and Moataz Dowaidar. 2008a. "Dysmorphic Features, Consanguinity and Cytogenetic Pattern of Congenital Heart Diseases: A Pilot Study from Mansoura Locality, Egypt." *International Journal of Health Sciences* 2 (2): 101–11. <https://www.ncbi.nlm.nih.gov/pubmed/21475491>.
288. Settin, Ahmad, Moataz Dowaidar, Rizk El-Baz, Ayman Abd-Al-Samad, Ibrahim El-Sayed, and Mahmoud Nasr. 2008. "Frequency of Factor V Leiden Mutation in Egyptian Cases with Myocardial Infarction." *Hematology* 13 (3): 170–74. <https://doi.org/10.1179/102453308X316158>.
289. Venit, Tomas, Moataz Dowaidar, Maxime Gestin, Syed Raza Mahmood, Ülo Langel, and Piergiorgio Percipalle. 2020. "Transcriptional Profiling Reveals Ribosome Biogenesis, Microtubule Dynamics and Expression of Specific lncRNAs to Be Part of a Common Response to Cell-Penetrating Peptides." *Biomolecules* 10 (11): 1567. <https://doi.org/10.3390/biom10111567>.